Transformation Potency Research Articles

Mutations in the BCR/ABL Kinase Encoding the Resistance to Imatinib Mesylate Do Not Modify the Sensitivity to Genotoxic Treatment.

Imatinib mesylate (IM), a selective inhibitor of ABL kinase activity, revolutionized the treatment of BCR/ABL-positive leukemias. Unfortunately, clinical and experimental observations reveal that resistance to IM is a rising problem, which obscures an otherwise very successful oncogene-targeted therapy. IM resistance can be achieved by point mutations in the kinase domain of BCR/ABL and have been detected in 50–90% of patients with acquired resistance to IM, including ~23% of the IM-naive patients. Strategies to enhance the effect of IM and eventually overcome the resistance are dose escalation, addition of a growth factor, and combinations with novel tyrosine kinase inhibitors like AMN107 and dasatinib, or with inhibitors targeting downstream BCR/ABL effectors, e.g. PI-3k. Unfortunately, resistance to other small molecule inhibitors is likely to appear, as well. Therefore, we tested the sensitivity of leukemia cells expressing IM-resistant BCR/ABL mutants to genotoxic agents. Baf3 cells expressing similar levels of p210BCR/ABL wild-type (WT) and Y253F, Y253H, E255K, E255V, T315I, M351T, and H396P mutants were established. These mutants were selected since they represent several functionally distinct ABL kinase domain regions, including P-loop (Y253F/H and E255K/V), the site of a hydrogen bond with IM (T315I), the activation loop hinge (M351T), and the activation loop (H396P). In addition, they exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to IM. Western analysis demonstrated similarity, but also differences in the patterns of tyrosine phosphorylated proteins in total cell lysates. As expected, these clones displayed different level of sensitivity to IM: T315I>Y253H>E255V>E255K=Y253F>M251T=H396P>WT. However, leukemia cells expressing the WT and IM-resistant BCR/ABL kinase mutants demonstrated similar sensitivity to cytotoxic drugs such as hydroxyurea (HU), mitomycin C (MMC), and N-Methyl N'-nitro-N-nitrosoguanidine (MNNG). Surprisingly, clones expressing IM-resistant BCR/ABL kinase mutants were more sensitive to γ-irradiation than their WT counterparts. γ-H2AX (histone H2AX phosphorylated on S139) nuclear foci, which serve as marker of DNA double-strand breaks (DSBs), the most lethal DNA lesions, were detected by immunofluorescence. Leukemia cells expressing WT and IM-resistant p210BCR/ABL proteins accumulated similar numbers of DSBs after MMC treatment and γ-irradiation. This observation suggests that leukemia cells expressing IM-resistant p210BCR/ABL mutants may be eliminated by genotoxic treatment, especially γ-irradiation. In addition, IM-resistant BCR/ABL kinase mutants, in contrast to the WT kinase may not be able to modulate the mechanisms protecting from apoptosis induced by γ-irradiation.

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Kinase domain (KD) mutations of Bcr-Abl interfering with imatinib binding are the major mechanism of acquired imatinib resistance in patients with Philadelphia chromosome-positive leukemia. Mutations of the ATP binding loop (p-loop) have been associated with a poor prognosis. We compared the transformation potency of five common KD mutants in various biological assays. Relative to unmutated (native) Bcr-Abl, the ATP binding loop mutants Y253F and E255K exhibited increased transformation potency, M351T and H396P were less potent, and the performance of T315I was assay dependent. The transformation potency of Y253F and M351T correlated with intrinsic Bcr-Abl kinase activity, whereas the kinase activity of E255K, H396P, and T315I did not correlate with transforming capabilities, suggesting that additional factors influence transformation potency. Analysis of the phosphotyrosine proteome by mass spectroscopy showed differential phosphorylation among the mutants, a finding consistent with altered substrate specificity and pathway activation. Mutations in the KD of Bcr-Abl influence kinase activity and signaling in a complex fashion, leading to gain- or loss-of-function variants. The drug resistance and transformation potency of mutants may determine the outcome of patients on therapy with Abl kinase inhibitors.

Metabolism of the Food-Associated Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by Human Intestinal Microbiota

2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is a putative human carcinogenic heterocyclic aromatic amine formed from meat and fish during cooking. Although the formation of hazardous PhIP metabolites by mammalian enzymes is well-documented, nothing is known about the PhIP transformation potency of human intestinal bacteria. In this study, the in vitro metabolism of PhIP by human fecal samples was investigated. Following anaerobic incubation of PhIP with stools freshly collected from six healthy volunteers, we found that PhIP was extensively transformed by the human intestinal bacteria. HPLC analysis showed that the six human fecal microbiota transformed PhIP with efficiencies from 47 to 95% after 72 h incubation, resulting in one major derivative. ESI-MS/MS, HRMS, 1D (1H, 13C, DEPT) and 2D (gCOSY, gTOCSY, gHMBC, gHSQC) NMR, and IC analysis elucidated the complete chemical identity of the microbial PhIP metabolite as 7-hydroxy-5-methyl-3-phenyl-6,7,8,9-tetrahydropyrido[3',2':4,5]imidazo[1,2-a]pyrimidin-5-ium chloride. At present, no information is available about the biological activity of this newly discovered bacterial PhIP metabolite. Our findings however suggest that bacteria derived from the human intestine play a key role in the activation or detoxification of PhIP, a digestive fate ignored so far in risk assessments. Moreover, the variation in transformation efficiency between the human microbiota indicates interindividual differences in the ability to convert PhIP. This may predict individual susceptibility to carcinogenic risk from this suspected dietary carcinogen.

Activation of Proestrogens from Hops (Humulus lupulus L.) by Intestinal Microbiota; Conversion of Isoxanthohumol into 8-Prenylnaringenin

Hop, an essential ingredient in most beers, contains a number of prenylflavonoids, among which 8-prenylnaringenin (8-PN) would be the most potent phytoestrogen currently known. Although a number of health effects are attributed to these compounds, only a few reports are available about the bioavailability of prenylflavonoids and the transformation potency of the intestinal microbial community. To test these transformations, four fecal samples were incubated with xanthohumol, isoxanthohumol (IX), and 8-PN. Upon incubation with IX, present in strong ales up to 4 mg/L, 36% was converted into 8-PN in one fecal sample and the estrogenic properties of the sample drastically increased. In an experiment with 12 fecal cultures, this conversion was observed in one-third of the samples, indicating the importance of interindividual variability in the intestinal microbial community. Eubacterium limosum was identified to be capable of this conversion (O-demethylation) of IX into 8-PN, and after strain selection, a conversion efficiency of 90% was achieved. Finally, strain supplementation to a nonconverting fecal sample led to rapid and high 8-PN production at only 1% (v/v) addition. Up to now, the concentration of 8-PN in beer was considered too low to affect human health. However, these results show that the activity of the intestinal microbial community could more than 10-fold increase the exposure concentration. Because prenylflavonoids are present in many beers with IX being the major constituent, the results raise the question whether moderate beer consumption might contribute to increased in vivo levels of 8-PN and even influence human health.

Investigation of the Biological Differences between Bcr-Abl Kinase Mutations Resistant to Imatinib.

Background: Bcr-Abl kinase domain (KD) mutations are a major cause of acquired resistance to imatinib. In some patients KD mutations have been detected prior to therapy, and P-loop mutations confer a particularly poor prognosis, suggesting an association with disease progression independent of imatinib therapy. We therefore compared the transforming potential of several frequent KD mutants with wild type (WT) Bcr-Abl in a variety of in vivo and in vitro assays.Experimental: We compared the growth rate of BaF3 cells expressing WT or KD mutants of Bcr-Abl (Q252H, Y253F, E255K, T315I, M351T, F359V, H396P, H396R) under optimal (10% FBS) and low serum conditions (1% FBS) over an 18-day period. In 10% FBS, all mutants except Y253F, showed a decreased growth rate relative to WT. However in low serum all mutants except Q252H, M351T and F359V and H396P had an increased growth rate relative to WT. To further validate the differences in growth rates direct competition assays were done. Equal cell numbers of WT and mutant were plated in the same flask in media containing either 10% or 1% FBS. The proportion of mutant clone was monitored by PCR amplification of Bcr-Abl and direct sequencing. In 10% FBS only Y253F dominated WT. In contrast all mutants except M351T were able to outgrow WT in 1% FBS. To compare the transformation potency of mutant vs. WT Bcr-Abl in primary cells, WT and several mutants were introduced in the MIG1 retroviral vector. Bone marrow cells from Balb/c mice were infected with retroviral supernatant containing comparable numbers of infectious particles. For assessment of B cell transformation, transduced cells from non 5-FU treated mice were plated in Whitlock-Witte cultures under limiting dilution conditions. The trend for B-cell transformation potential was Y253F>E255K>WT>T315I>H396P>M351T. To compare the potency of the mutants for induction of myeloproliferative disease, lethally irradiated recipients were transplanted with transduced cells from 5-FU treated animals. The mice were sacrificed when the white blood cell count exceeded 200/nl or the animals appeared moribund. In WT animals disease latency was approximately 19 days with median survival 23 days. No significant differences between the mutants and WT were observed, although there was a trend toward longer survival in mice with the M351T and H396P mutations. To screen for biochemical differences between the mutants, we compared the activation of signaling pathways in BaF3 cells expressing mutant and WT Bcr-Abl, including Akt, Erk, Jnk, CrkL, Cbl, Stat3 and Stat5, but failed to detect differences. However, significant differences in the banding patterns were observed on phosphotyrosine blots from cellular lysates.Conclusion: Our data suggest that the P-loop mutants Y253F and E255K have greater transforming potential than WT, whereas M351T and H396P are less potent. Our inability to detect significant differences in the murine leukemia disease model may be due to the rapid course of disease that precludes the detection of more subtle differences. Our data are consistent with the clinical observation of the poor prognosis of patients with P-loop mutations and the reversal to WT Bcr-Abl on imatinib withdrawal that has been observed in some patients with non P-loop mutations. In addition, the ability of certain mutants to outcompete WT under suboptimal conditions may allow cells harboring these mutations to populate less hospitable niches in the bone marrow, until selected by imatinib.

Human Colon Microbiota Transform Polycyclic Aromatic Hydrocarbons to Estrogenic Metabolites

Ingestion is an important exposure route for polycyclic aromatic hydrocarbons (PAHs) to enter the human body. Although the formation of hazardous PAH metabolites by human biotransformation enzymes is well documented, nothing is known about the PAH transformation potency of human intestinal microbiota. Using a gastrointestinal simulator, we show that human intestinal microbiota can also bioactivate PAHs, more in particular to estrogenic metabolites. PAH compounds are not estrogenic, and indeed, stomach and small intestine digestions of 62.5 nmol naphthalene, phenanthrene, pyrene, and benzo(a)pyrene showed no estrogenic effects in the human estrogen receptor bioassay. In contrast, colon digests of these PAH compounds displayed estrogenicity, equivalent to 0.31, 2.14, 2.70, and 1.48 nmol 17α-ethynylestradiol (EE2), respectively. Inactivating the colon microbiota eliminated these estrogenic effects. Liquid chromatography–mass spectrometry analysis confirmed the microbial PAH transformation by the detection of PAH metabolites 1-hydroxypyrene and 7-hydroxybenzo(a)pyrene in colon digests of pyrene and benzo(a)pyrene. Furthermore, we show that colon digests of a PAH-contaminated soil (simulated ingestion dose of 5 g/day) displayed estrogenic activity equivalent to 0.58 nmol EE2, whereas stomach or small intestine digests did not. Although the matrix in which PAHs are ingested may result in lower exposure concentrations in the gut, our results imply that the PAH bioactivation potency of colon microbiota is not eliminated by the presence of soil. Moreover, because PAH toxicity is also linked to estrogenicity of the compounds, the PAH bioactivation potency of colon microbiota suggests that current risk assessment may underestimate the risk from ingested PAHs.

Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase.

Cellular transformation occurs only in cells that express both ErbB1 and ErbB4 receptors, but not in cells expressing only one or the other of these receptors. However, when both receptors are coexpressed and ligand-stimulated, they interact with virtually the same adaptor/effector proteins as when expressed singly. To reveal the underlying regulatory mechanism of the kinase/phosphatase network in ErbB homo- and heterodimer receptor signaling, extracellular signal-regulated kinase (ERK) and Akt activities were evaluated in the presence of several enzyme inhibitors in ligand-induced cells expressing ErbB1 (E1), ErbB4 (E4), and ErbB1/ErbB4 (E1/4) receptor. The PP2A inhibitor okadaic acid showed receptor-specific inhibitory profiles for ERK and Akt activities. Moreover, B-Raf isolated only from E1/4 cells could induce in vitro phosphorylation for MEK; this B-Raf kinase activity was abolished by pretreatment of the cells with okadaic acid. Our study further showed that the E1/4 cell-specific B-Raf activity was stimulated by PLC gamma and subsequent Rap1 activation. The present study suggests that B-Raf kinase, which was specifically activated in the cells coexpressing ErbB1 and ErbB4 receptors, elevates total ERK activity within the cell and, therefore, can induce cellular transformation.

Domain Structure of Pleiotrophin Required for Transformation

The pleiotrophin (PTN) gene (Ptn) is a potent proto-oncogene that is highly expressed in many primary human tumors and constitutively expressed in cell lines derived from these tumors. The product of the Ptn gene is a secreted 136-amino acid heparin binding cytokine with distinct lysine-rich clusters within both the N- and C-terminal domains. To seek domains of PTN functionally important in neoplastic transformation, we constructed a series of mutants and tested their transforming potential by four independent criteria. Our data establish that a domain within PTN residues 41 to 64 and either but not both the N- or C-terminal domains are required for transformation; deletion of both the N and C termini abolishes the transformation potential of PTN. Furthermore, deletion of two internal 5-amino acid residue repeats enhances the transformation potency of PTN 2-fold. Our data indicate that PTN residues 41-64 contain an essential domain for transformation and suggest the hypothesis that this domain requires an additional interaction of the highly basic clusters of the N or C terminus of PTN with a negatively charged "docking" site to enable the transforming domain itself to engage and initiate PTN signaling through its cognate receptor.

Role of the aromatic hydrocarbon receptor in the suppression of cytochrome P-450 2C11 by polycyclic aromatic hydrocarbons

The aromatic hydrocarbon (AH) receptor mediates the induction of cytochromes P-450 (CYP) of the CYP1A subfamily caused by polycyclic aromatic hydrocarbons (PAHs). CYPIA induction by PAHs is accompanied by down-regulation of CYP2C11, the predominant CYP expressed constitutively in the liver of male rats. We performed a structure-activity relationship study with a series of PAHs of the anthracene class in order to determine if the AH receptor is involved in CYP2C11 down-regulation. Anthracene, benz[a]anthracene, dibenz[a,c]anthracene, dibenz[a,h]anthracene, 7,12-dimethyl[a]anthracene, as well as 2,3,7,8-tetrachlorodibenzo- p-dioxin and 3-methylcholanthrene decresed CYP2C11 immunoreactive protein levels to varying degrees in primary rat hepatocytes cultured on a laminin-rich extracellular matrix. The binding affinity of the PAHs for the rat liver cytosolic AH receptor correlated with the potency for transforming the cytosolic AH receptor to its DNA-binding form. In addition, the ability of the PAHs to suppress CYP2C11 correlated with both the AH receptor binding affinity and the AH receptor transformation potency. These results suggests the AH receptor plays a role in the down-regulation of CYP2C11 caused by PAHs.

Transformation of rat tracheal epithelial cells to immortal growth variants by particulate and soluble nickel compounds

The cytotoxicity and transforming activity of nickel subsulfide, nickel oxide and nickel sulfate was studied by assays of colony-forming efficiency and of transformation of rat tracheal epithelial (RTE) cells to enhanced growth variants (EGVs) and immortal growth variants (IGVs). Nickel subsulfide caused dose-dependent cytotoxicity between 1 and 5 μg/ml, whereas the cytotoxic range of nickel oxide and nickel sulfate was 50–200 μg/ml and 60–130 μg/ml, respectively. At lower concentrations, nickel sulfate caused modest (up to 126%) growth stimulation. During the initial 24-h treatment period, internalized nickel subsulfide particles were observed in phagocytic vesicles in cells near the periphery of all RTE cell colonies, whereas nickel oxide particles were not internalized but had adhered to both the cells and the tissue culture dish. After 7–10 days of the transformation assay, nickel subsulfide particles were no longer visible, but nickel oxide particles remained on the dish for the duration of the 5 week assay. During weeks 3–5 of the transformation assay, internalized nickel oxide particles were observed in non-vacuolated cells at the periphery of the colonies. All 3 nickel compounds significantly ( p < 0.05) increased the transformation frequency of RTE cells to EGVs at moderately cytotoxic concentrations; the order of potency was Ni 3S 2 > NiO = NiSO 4. MNNG, the positive control, was twice as active as nickel subsulfide at 1 3 the concentration and 1 6 the duration of treatment. EGVs induced by MNNG, nickel subsulfide and nickel sulfate were cloned and converted to IGVs at frequencies of 44, 24 and 43%, respectively. In contrast, EGVs transformed by nickel oxide rarely converted to IGVs (13%). All nickel-induced IGVs were immunohistochemically epithelial, mitotically active, aneuploid and exhibited high plating efficiencies. Our results suggest that respiratory epithelial cells are targets for the transforming capabilities of several nickel compounds but that the potency and mechanism of transformation by various forms of nickel may be different according to the physico-chemical properties of each compound.

Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products

Oncogenic activation of the proto-oncogene c-abl in human leukemias occurs as a result of the addition of exons from the gene bcr and truncation of the first abl exon. Analysis of tyrosine kinase activity and quantitative measurement of transformation potency in a single-step assay indicate that variation in bcr exon contribution results in a functional difference between p210bcr-abl and p185bcr-abl proteins. Thus, foreign upstream sequences are important in the deregulation of the kinase activity of the abl product, and the extent of deregulation correlates with the pathological effects of the bcr-abl proteins.

Genetic determinants of neoplastic transformation by the retroviral oncogene v-erbB.

The retroviral oncogene v-erbB is a mutant version of the gene (c-erbB or ERBB1) that encodes the cell-surface epidermal growth factor receptor (EGFR). The mutations take three forms: (i) a large deletion that removes the entire ligand-binding domain of EGFR, (ii) smaller deletions that affect the carboxyl-terminal domain of EGFR, and (iii) point mutations that cause conservative substitutions of amino acids. Previous work has shown that, in the absence of the large deletion, ERBB1 cannot transform cells autonomously. Here we report that when the large deletion is present, no other mutation is required for ERBB1 to transform established rodent fibroblasts to a tumorigenic phenotype. In particular, there is no need for deletions affecting the carboxyl terminus of the gene product. It appears, therefore, that removal of the ligand-binding domain from the EGFR suffices to create a transforming protein. Deletions at the carboxyl terminus of the EGFR apparently play only a secondary role in transformation by affecting the host range and perhaps the potency of transformation; and there is as yet no evidence to implicate point mutations in the activation of ERBB1 to an oncogene. Our findings support the view that augmented activity of the EGFR can contribute to tumorigenesis.

Metabolic Relations between Methylxanthines and Methyluric Acids in Coffea L.

Metabolism of purine alkaloids in the leaves of Coffea dewevrei De Wild et Durand var excelsa Chev, Coffea liberica Bull ex Hiern and Coffea abeokutae Cramer was studied by analyzing leaf discs collected during vegetative development and by feeding the following radioactive tracers: [(14)C]theobromine, [(14)C]caffeine, and [(14)C]theacrine (1,3,7,9-tetramethyluric acid). Their principal metabolites were quantitatively and qualitatively determined. All three species convert the precursors to the same radioactive products, and proceed through the same four maturity stages characterized by the alkaloid accumulation pattern and by a particular transformation potency: (stage 1) young plant accumulating caffeine, transforms theobromine to caffeine; (stage 2) caffeine is gradually replaced by theacrine, theobromine and caffeine are converted to theacrine; (stage 3) theacrine disappears whereas liberine (O(2), 1,9-thrimethyluric acid) accumulates, theacrine is metabolized to liberine; (stage 4) branched-out plant containing liberine but no theacrine, caffeine is converted rapidly to liberine via theacrine. Methylliberine (O(2),1,7,9-tetramethyluric acid), presumably the direct precursor of liberine, is occasionally found in low concentrations at stage 3 and 4.The collective term ;liberio-excelsoid' introduced by geneticists for the numerous races or species of Pachycoffea is in accordance with the phytochemical equality found in this work.

In vitro toxicity and transformation potency of nickel compounds.

An in vitro bioassay utilizing BHK-21 cells in culture is used to determine the relative transformation potential of a number of nickel compounds including, as relatively insoluble particulates a known carcinogen (Ni3S2) and several oxides either of commercial interest or found in the working environment in the metal industry (e.g., NiO), and a soluble salt [Ni(CH3COO)2]. Although a wide range of transformation potency is found as a function of the dose of Ni per area of culture, all substances produce the same number of transformed colonies at the same degree of toxicity (e.g., 50% survival). If toxicity is a direct measure of intracellular concentration, then apparently nickel per se is the ultimate transforming agent independent of source or uptake mechanism.

In vitro Toxicity and Transformation Potency of Nickel Compounds

An in vitro bioassay utilizing BHK-21 cells in culture is used to determine the relative transformation potential of a number of nickel compounds including, as relatively insoluble particulates a known carcinogen (Ni3S2) and several oxides either of commercial interest or found in the working environment in the metal industry (e.g., NiO), and a soluble salt [Ni(CH3COO)2]. Although a wide range of transformation potency is found as a function of the dose of Ni per area of culture, all substances produce the same number of transformed colonies at the same degree of toxicity (e.g., 50% survival). If toxicity is a direct measure of intracellular concentration, then apparently nickel per se is the ultimate transforming agent independent of source or uptake mechanism.